Approval · Notice of Compliance 38115 · 2026
BLEOMYCIN FOR INJECTION: Notice of Compliance 38115
Issued August 12, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38115
- Date
- August 12, 2026
- Company
- Fresenius Kabi Canada LtdToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Change in the drug product manufacturing process. Replacement of a primary container closure system. Change in the batch size for the drug product
- Canadian reference product
- BLENOXANE (Bristol Laboratories Of Canada)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BLEOMYCIN FOR INJECTION | Not yet assigned | — |
Medicinal ingredients
- BLEOMYCIN SULFATE 15 UNIT per VIAL